Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model.
carfilzomib
desensitization
kidney transplant
lulizumab
sensitization
Journal
Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
25
05
2020
revised:
23
07
2020
accepted:
20
08
2020
pubmed:
9
9
2020
medline:
22
6
2021
entrez:
8
9
2020
Statut:
ppublish
Résumé
Sensitized patients are difficult to transplant due to pre-formed anti-donor immunity. We have previously reported successful desensitization using carfilzomib and belatacept in a non-human primate (NHP) model. Here we evaluated selective blockade of the co-stimulatory signal (CD28-B7) with Lulizumab, which preserves the co-inhibitory signal (CTLA4-B7). Five maximally MHC-mismatched pairs of NHPs were sensitized to each other with two sequential skin transplants. Individuals from each pair were randomized to either desensitization with once-weekly Carfilzomib (27mg/m
Identifiants
pubmed: 32898569
pii: S0085-2538(20)31044-9
doi: 10.1016/j.kint.2020.08.020
pmc: PMC7785689
mid: NIHMS1631498
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Oligopeptides
0
carfilzomib
72X6E3J5AR
Abatacept
7D0YB67S97
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-172Subventions
Organisme : NIAID NIH HHS
ID : U19 AI131471
Pays : United States
Informations de copyright
Copyright © 2020 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.